Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III NPB-01 vs methylprednisolone in steroid-refractory autoimmune encephalitis
jRCT2061210070Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of immune globulin in Autoimmune Encephalitis (AE), Autoimmune Limbic Encephalitis (ALE), anti-NMDA receptor encephalitis and 2 more (2 arms), sponsored by Takeda. Primary endpoint: Percentage of responders by CASE score at Week 4. Started Mar 2022; status: completed.
02
Drugs
immune globulin
03
Conditions
Autoimmune Encephalitis (AE)Autoimmune Limbic Encephalitis (ALE)anti-NMDA receptor encephalitisBickerstaff brainstem encephalitis (BBE)Hashimoto encephalopathy (HE)
Beyond the preview
Go deeper on jRCT2061210070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210070.